aTyr Pharma (ATYR) 2025 Conference Transcript

Summary of aTyr Pharma (ATYR) 2025 Conference Call Company Overview - Company: aTyr Pharma (ATYR) - Event: 2025 Jefferies Global Healthcare Conference - Focus: Lead program for pulmonary sarcoidosis and updates on other indications Key Points on Pulmonary Sarcoidosis Program - Phase Three Study: Baseline demographics presented at ATS, showing expected characteristics in race, gender, and age of sarcoidosis patients [3][4] - Steroid Dosage: Average steroid dose at entry for the phase three trial was 10.5 mg, slightly lower than the 12-13 mg in phase two, aligning with treatment guidelines [4][6] - Patient Management: Patients on lower steroid doses are more sensitive to reductions, with a focus on managing flare-ups in the placebo group [12][13] - FDA Feedback: FDA recommended simplifying the statistical analysis plan to focus on the last four weeks of treatment, which increases the power to detect smaller differences [17][18] - Power Assumptions: The trial is powered to show a statistically significant absolute reduction of 3 mg in steroid use compared to placebo [22][23] - Market Opportunity: The target population for the therapy is larger than initially estimated, with 150,000 to 160,000 steroid-dependent patients in the U.S. [48][49] Other Indications and Updates - Scleroderma-Related ILD Study: Interim data showed promising results in skin improvement, particularly in diffuse scleroderma patients [60][62] - Potential for Broader Applications: Interest in expanding the use of epsofitimod to other forms of interstitial lung disease (ILD) and connective tissue disease ILD, with a potential market value exceeding $5 billion [70][71] Financial Position - Cash Position: The company has sufficient cash to support operations through the upcoming readouts and for at least another year beyond that [72] Conclusion - aTyr Pharma is positioned to potentially change treatment paradigms in pulmonary sarcoidosis and other ILDs, with significant market opportunities and a strong financial position to support ongoing and future trials.